Aug. 26 at 6:14 PM
$HSDT $HASSAN77, you are right about the company’s track record in the past. However, I do believe timing is everything in regards to investing.
With July 2025 report on statistically significant greater improvements in gait and/or balance deficit due to stroke with active PoNS therapy with and without including additional data from the OLS using statistical methods to balance baseline characteristics, and is on track to submit for FDA authorization for stroke in the third quarter of 2025, with the plan to achieve FDA authorization by the end of 2025 or early in 2026.
Along other catalysts like on July 11, 2025, the Company successfully secured a product listing agreement with HealthPro, Canada’s leading group purchasing organization representing over 2,000 hospitals. This listing enables the Company to actively promote PoNS to participating healthcare institutions across Canada and now with five major payer to authorize claims for payment for the PoNS Device. The sky is the limit!
